Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge

He was the only executive to do so before a Senate Health Committee hearing that also included the CEOs of Novo Nordisk and Sanofi.

This article was originally published on CNBC